NewEdge Advisors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

NewEdge Advisors’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-15	Closed	-$40	–	3659
2023 Q1	$40	Hold	15	–	–	﹤0.01%	3367
2022 Q4	$0	Buy	+15	New	+$65	﹤0.01%	4233

Other funds holding SYRS

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Adage Capital Partners

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

NewEdge Advisors's SYRS Position: Q2 2023 in Review

NewEdge Advisors sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2023, closing a stake of 15 shares — an estimated $40 sold.

NewEdge Advisors first reported a position in SYRS in Q4 2022 and held it in 2 quarters. The position peaked at $40 in Q1 2023. 53 funds tracked by Wall St. Rank hold SYRS as of Q2 2023.

NewEdge Advisors reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
NewEdge Advisors sold 15 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $40.
NewEdge Advisors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
NewEdge Advisors's Syros Pharmaceuticals, Inc. Common Stock position peaked at $40 in Q1 2023.
53 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on NewEdge Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.